Economic Analysis of Initial HIV Treatment
- 1 January 2001
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (1) , 95-104
- https://doi.org/10.2165/00019053-200119010-00007
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1999
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Cost effectiveness of highly active antiretroviral therapy in HIV-infected patientsAIDS, 1999
- Comparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral LoadJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Health Economics in HIV DiseasePharmacoEconomics, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- United Kingdom AIDS survival in adultsAIDS, 1996
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/??l in 5 European CountriesPharmacoEconomics, 1994
- AIDS Specialist Versus Generalist Ambulatory Care for Advanced HIV Infection and Impact on Hospital UseMedical Care, 1994